As International Vice President of Cancer Research at Glaxo Wellcome (now GSK) and Associate Division Director of Experimental Therapy at Burroughs Wellcome, Dr. Spector worked closely with all branches of drug development, including toxicology, clinical research, clinical pharmacology, marketing, regulatory, patents, analytical chemistry, process chemistry, and pharmaceutical formulations. He has also had interactions with the FDA to advance the development of drug candidates. In addition to working on many other projects, Dr. Spector was the International Project Leader for three compounds that evolved from personal initiatives within his research group.
As Chief Scientific Officer of Adherex Technologies (now Fennec Pharma), Dr. Spector designed and led the Phase II clinical trial of eniluracil/5-fluorouracil/leucovorin for metastatic breast cancer. He produced the Protocol, the Investigators Brochure, various other FDA documents, and oversaw all clinical activities (ref. 105 in Publications: click to read Eniluracil MBC 2014). In addition, Dr. Spector has written, defended, and challenged numerous patents.
As President of Spector Consulting Services, Dr. Spector continues to have broad-based interest in many therapeutic areas, including:
- CANCER THERAPY
- ANTIVIRAL AGENTS
- OTHER ANTIINFECTIVE AGENTS
- PHARMACODYNAMIC AGENTS